v3.25.2
Summary of Significant Accounting Policies (Tables)
 6 Months Ended
Jun. 30, 2025
Accounting Policies [Abstract]  
Schedule of Concentration of Risk, by Risk Factor and Significant Payer For each significant payor and customer, revenue as a percentage of total revenue and accounts receivable as a percentage of total accounts receivable are as follows:
 
 Revenue
 Three Months Ended
June 30,		Six Months Ended
June 30,
 2025202420252024
Customer A23 %23 %23 %25 %
Customer B16 %25 %17 %21 %
Customer C*11 %10 %*
Customer D10 %***

Accounts Receivable, Net
 June 30, 2025December 31, 2024
Customer A14 %13 %
Customer B22 %25 %
*Less than 10%.
Schedule of Disaggregation of Revenue
The following table includes the Company's revenues as disaggregated by payor and customer category (in thousands):
 
 Three Months Ended June 30,Six Months Ended June 30,
 2025202420252024
Revenue:
Commercial$8,811 $8,672 $17,571 $15,535 
Government3,926 3,457 7,633 7,643 
Client direct bill(1)4,371 2,910 7,367 6,194 
Other(2)94 25 129 107 
Total revenue$17,202 $15,064 $32,700 $29,479 
(1)Includes hospitals, other laboratories, etc.
(2)Includes patient self-pay.
Schedule of Cash and Cash Equivalents
Cash, cash equivalents, and restricted cash presented in the accompanying condensed statements of cash flows consist of the following (in thousands):
 
 June 30, 2025December 31, 2024
Cash and cash equivalents$30,033 $22,036 
Restricted cash200 200 
Total cash, cash equivalents and restricted cash$30,233 $22,236 
Schedule of Restricted Cash and Cash Equivalents
Cash, cash equivalents, and restricted cash presented in the accompanying condensed statements of cash flows consist of the following (in thousands):
 
 June 30, 2025December 31, 2024
Cash and cash equivalents$30,033 $22,036 
Restricted cash200 200 
Total cash, cash equivalents and restricted cash$30,233 $22,236 
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share
Potentially dilutive securities not included in the calculation of diluted net loss per share, because to do so would be anti-dilutive, are as follows (in common stock equivalent shares):
 
 June 30, 2025June 30, 2024
Warrants to purchase common stock580,339 409,108 
Common stock options564,441 817,046 
Restricted stock units1,679,624 1,679,469 
Employee stock purchase plan54,454 38,299 
Total2,878,858 2,943,922